AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
We enclose a Press Release that is being issued by the Company in connection with USFDA approval received by Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated August 4, 2023, please note that the audio recording of the earnings call on the unaudited financial results for the first quarter ended June 30, 2023, held on August 14, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link: https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/ AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find attached Copies of Unaudited Financial Results for the quarter ended June 30, 2023 published newspapers. Q1FY24 Quarterly Result Announced for Aurobindo Pharma Ltd.
Pharmaceuticals company Aurobindo Pharma announced Q1FY24 results: Revenue from Operations at Rs 6,850.5 croreore increased by 9.9% YoY US formulations revenue increased by 11.2% YoY to Rs 3,304 crore Europe formulation revenue stood at Rs 1,837 crore, with an increase of 18.6% YoY Growth Markets revenue grew by 12.9% YoY to Rs 486 crore ARV revenue stood at Rs 190 crore API revenue grew by 14.0% YoY to Rs 1,033 crore EBITDA before Forex and Other income stood at Rs 1,151.4 crore; EBITDA margin for the quarter was 16.8%. Research & Development (R&D;) spend at Rs 387.6 crore, 5.7% of revenues (Q4FY23: 6.3%) Received final approval for 19 ANDAs including 7 injectable products from the USFDA Net Profit after Share of Profit/Loss of JV and minority interest stood at Rs 570.8 crore, as against Rs 520.5 crore in Q1FY23 Basic & Diluted EPS is Rs 9.74 per share Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said, “We are pleased to start the new financial year on a good note with strong top-line growth and margin expansion aided by improved performance across our key markets. With our product pipeline continuing to advance, and execution of growth drivers proceeding as planned, we are confident that our fundamental strengths position us to create an upward trajectory. Looking ahead, we are confident in executing our growth initiatives and creating long-term value for our shareholders.” Result PDF
Aurobindo Pharma Q1 Results: Net profit drops 22% to 540 crore, revenue up 10% YoY
Aurobindo Pharma Q1 Results: The pharma major's revenue from operations during the first quarter of current fiscal stood at 6,850.5 crore, registering a rise of 9.9 per cent, compared to 6,236 crore in the year-ago period. Aurobindo Pharma's Q1 net up 9.7 per cent at Rs 570 crore
Revenue up 9.9 per cent at Rs 6,850 crore, as against Rs 6,236 crore in the same period last year AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on un-audited financial results for the first quarter ended June 30, 2023. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We enclose a copy of press release on Un-audited financial results for the first quarter ended June 30, 2023. AUROBINDO PHARMA LTD. - 524804 - Un-Audited Financial Results For The Quarter Ended June 30, 2023.
Un-audited financial results for the quarter ended June 30, 2023. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Change in Directorate
The Board of Directors in its meeting held today, August 12, 2023, has accepted the resignation of Dr. M. Sivakumaran as Whole-time Director and Director of the Company on close of business hours of August 24, 2023.